Palatin Technologies, Inc.'s (PTN) shares were losing more than 38 percent in pre-market activity on the NYSE after the biopharmaceutical company announced that co-primary sign endpoint and secondary sign endpoints in its PL9643 MELODY-1 pivotal Phase 3 clinical trial in dry eye disease did not achieve statistical significance.